Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Conditions: Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasm Interventions: Other: Screening Blood Tests; Diagnostic Test: Endoscopic Ultrasound; Combination Product: Magnetic Resonance Imaging; Combination Product: Magnetic Resonance Cholangiopancreatography Sponsors: Dana-Farber Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Conditions: Adenocarcinoma; Stomach Neoplasm; Gastroesophageal-junction Cancer; Oligometastatic Disease; Metastatic Cancer; Metastatic Gastric Cancer; Adenocarcinoma of the Stomach; Gastroesophageal Junction Adenocarcinoma; Metastatic Adenocarcinoma Interventions: Radiation: Radiotherapy targeted to the primary lesion; Radiation: Radiotherapy targeted to the metastatic lesions; Biological: Anti-PD-1 monoclonal antibody; Biological: Trastuzumab; Drug: Chemotherapy; Procedure: R0 total/subtotal gastrectomy with D2 lymphadenectomy; Procedure: Metastasectomy; Procedure: Local ablative therapies Sponsors: Fudan University Recru...
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase Ib/II Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
Conditions: Esophagogastric Adenocarcinoma Interventions: Drug: Sacituzumab govitecan Sponsors: Institut f ür Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: SHR-A1811; Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Conditions: Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation Interventions: Drug: Pembrolizumab; Drug: Trastuzumab Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Observation of Perioperative FOLFIRINOX for Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Ductal Adenocarcinoma; Oligometastatic Disease Interventions: Drug: FOLFIRINOX chemotherapy Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Most Total Pancreatectomies for Ductal Adenocarcinoma Can Be Replaced by Whipple Over the Splenic Artery: A Before and After Study
Conditions: Ductal Adenocarcinoma of the Pancreas Interventions: Procedure: Whipple over the splenic artery; Procedure: Total pancreatectomy Sponsors: National Taiwan University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance
Conditions: Gastric Adenocarcinoma Interventions: Drug: cadonilimab combined +paclitaxel (albumin-bound) Sponsors: China Medical University, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Conditions: Gastric; Colorectal Adenocarcinoma Interventions: Drug: tislelizumab Sponsors: China Medical University, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression
Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 6, 2023 Category: Pharmaceuticals Source Type: clinical trials
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Conditions: Pancreas Cancer; Pancreas Adenocarcinoma Interventions: Drug: Capecitabine Sponsors: Lee Ocuin, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Conditions: Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: External Beam Radiation Therapy; Other: Flotufolastat F-18; Drug: Lutetium Lu 177 PSMA-10.1; Procedure: Positron Emission Tomography; Procedure: Single Photon Emission Computed Tomography Sponsors: Emory University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma
Conditions: Lung Adenocarcinoma; Local Cryoablation Sponsors: China-Japan Friendship Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Conditions: Pancreatic Ductal Adenocarcinoma; Non-Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor; KRAS G12V Interventions: Drug: AFNT-211 Sponsors: Affini-T Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
